Peptides News and Research

RSS

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

5 Oct 2013

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com.

4 Oct 2013

Researchers develop new type of E. coli that kills bacteria responsible for hard-to-treat infections

The notorious bacteria E. coli is best known for making people sick, but scientists have reprogrammed the microbe - which also comes in harmless varieties - to make it seek out and fight other disease-causing pathogens.

3 Oct 2013

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Resveratrol, a naturally occurring polyphenol compound produced by the skin of red grapes and peanuts, and found in red wine, has been touted as a beneficial supplement due to its anti-inflammatory and antioxidant properties.

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis.

27 Sep 2013

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

The National Cancer Institute awarded Chrysalis BioTherapeutics a $1.5 million contract to continue development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. The project is a collaboration between Chrysalis, Baylor College of Medicine, and the University of Texas Medical Branch (UTMB).

24 Sep 2013

Inflammation tracks mania course

Markers of inflammation are elevated in patients who are hospitalized for acute mania, a study shows.

24 Sep 2013

Researchers report encouraging results from T1DAL study on type 1 diabetes

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby MD, PhD from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

23 Sep 2013

Cellectricon awards Cellaxess ACE project grant to support research in cell biology

Cellectricon, a leading provider of advanced cell-based screening technologies and services, has announced the two winners of its Cellaxess ACE project grant, supporting cutting-edge research in cell biology.

From Cellectricon 21 Sep 2013

Researchers develop brown fat detection method to combat obesity

When it comes to fat, you want the brown type and not so much of the white variety because brown fat burns energy to keep you warm and metabolically active, while white fat stores excess energy around your waist, causing health problems. Researchers at The University of Texas Health Science Center at Houston Medical School are studying brown fat with a goal of fighting obesity.

19 Sep 2013

New series of lectures focus on rodents, medicines and drug developments

Rodents, medicines and drug developments are all on the agenda during a new series of public lectures being staged by the University of Greenwich's Faculty of Engineering & Science.

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Researchers develop synthetic peptide that could be a new class of drugs for heart disease

Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

18 Sep 2013

New method to target, eliminate cancer-supporting macrophages in mouse tumors

When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.

17 Sep 2013

Researchers identify new link between meal times and daily changes in immune system

A new link between meal times and daily changes in the immune system has been identified by UC San Francisco researchers, and has led them to question assumptions about the roles of specific immune cells in infection and allergy.

17 Sep 2013

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

After focusing on confirming the utility and quantitative precision of the SISCAPA-MALDI workflow in the collaboration's first phase, Bruker said it plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities.

16 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

Peptides News and Research

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

Researchers develop new type of E. coli that kills bacteria responsible for hard-to-treat infections

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

Inflammation tracks mania course

Researchers report encouraging results from T1DAL study on type 1 diabetes

Cellectricon awards Cellaxess ACE project grant to support research in cell biology

Researchers develop brown fat detection method to combat obesity

New series of lectures focus on rodents, medicines and drug developments

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Researchers develop synthetic peptide that could be a new class of drugs for heart disease

New method to target, eliminate cancer-supporting macrophages in mouse tumors

Researchers identify new link between meal times and daily changes in immune system

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News